Moderna (Moderna) FCF Margin % : 14.29% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Moderna FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Moderna's Free Cash Flow for the three months ended in Dec. 2023 was $402 Mil. Moderna's Revenue for the three months ended in Dec. 2023 was $2,813 Mil. Therefore, Moderna's FCF Margin % for the quarter that ended in Dec. 2023 was 14.29%.

As of today, Moderna's current FCF Yield % is -8.95%.

The historical rank and industry rank for Moderna's FCF Margin % or its related term are showing as below:

MRNA' s FCF Margin % Range Over the Past 10 Years
Min: -1022.92 Med: -16.18 Max: 714.96
Current: -56.63

During the past 8 years, the highest FCF Margin % of Moderna was 714.96%. The lowest was -1022.92%. And the median was -16.18%.

MRNA's FCF Margin % is ranked better than
60.31% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs MRNA: -56.63

Moderna FCF Margin % Historical Data

The historical data trend for Moderna's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna FCF Margin % Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,022.92

714.96

75.19

24.27

-56.63

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															30.49	-72.80	-363.61	-97.37	14.29

Competitive Comparison of Moderna's FCF Margin %

For the Biotechnology subindustry, Moderna's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Moderna's FCF Margin % falls into.

Moderna FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Moderna's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3825	/	6754
	=	-56.63 %

Moderna's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	402	/	2813
	=	14.29 %

Moderna FCF Margin % Related Terms

Thank you for viewing the detailed overview of Moderna's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (Moderna) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany 0QF:Germany 0QF:Germany 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Executives

Stephen Hoge	officer: President	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock	officer: Chief Financial Officer	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger	officer: Chief Legal Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay	officer: Chief Commercial Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel	director, officer: Chief Executive Officer	320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres	officer: See Remarks	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline	officer: Chief Financial Officer	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez	officer: See Remarks	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan	director	AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson	officer: General Counsel and Secretary	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115